Respiratory disease in very-low-birthweight infants after prenatal thyrotropin-releasing hormone and glucocorticoid. TRH Study Group.

@article{Ballard1992RespiratoryDI,
  title={Respiratory disease in very-low-birthweight infants after prenatal thyrotropin-releasing hormone and glucocorticoid. TRH Study Group.},
  author={Roberta A. Ballard and Philip L. Ballard and Robert K. Creasy and James Padbury and D. Polk and Michael Bracken and Fernando Moya and Ian Gross},
  journal={Lancet},
  year={1992},
  volume={339 8792},
  pages={510-5}
}
Although prenatal glucocorticoid treatment reduces neonatal respiratory morbidity, respiratory distress syndrome and chronic lung disease (CLD) develop in many very-low-birthweight infants despite therapy. To investigate the effect of additional prenatal treatment with thyrotropin-releasing hormone (TRH), we did a multicentre, blinded, randomised trial. 404 women with threatened preterm delivery at less than 32 weeks' gestation received betamethasone plus TRH (4 doses of 400 micrograms 8-hourly… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Prenatal interventions to prevent bronchopulmonary dysplasia in animal models: a systematic review.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians • 2016

Similar Papers

Loading similar papers…